Kelly Maloney
Concepts (373)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 40 | 2025 | 292 | 5.840 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2025 | 81 | 1.740 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 17 | 2025 | 1695 | 1.330 |
Why?
| | Down Syndrome | 6 | 2023 | 492 | 1.320 |
Why?
| | Burkitt Lymphoma | 3 | 2024 | 60 | 0.980 |
Why?
| | Asparaginase | 8 | 2020 | 30 | 0.880 |
Why?
| | Fishes | 1 | 2024 | 100 | 0.850 |
Why?
| | Agriculture | 1 | 2024 | 102 | 0.830 |
Why?
| | Leukemia, Myeloid, Acute | 6 | 2024 | 620 | 0.790 |
Why?
| | Child | 73 | 2025 | 22037 | 0.760 |
Why?
| | Bayes Theorem | 1 | 2024 | 407 | 0.760 |
Why?
| | Consolidation Chemotherapy | 2 | 2019 | 10 | 0.690 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2025 | 1060 | 0.660 |
Why?
| | Child, Preschool | 48 | 2025 | 11097 | 0.630 |
Why?
| | Ecosystem | 1 | 2024 | 592 | 0.610 |
Why?
| | Disease-Free Survival | 12 | 2024 | 690 | 0.580 |
Why?
| | Leukemia | 4 | 2021 | 238 | 0.570 |
Why?
| | Oncogene Proteins, Fusion | 6 | 2024 | 215 | 0.560 |
Why?
| | Mercaptopurine | 5 | 2017 | 16 | 0.540 |
Why?
| | Prognosis | 16 | 2025 | 4031 | 0.510 |
Why?
| | Recurrence | 12 | 2025 | 1060 | 0.490 |
Why?
| | Antineoplastic Agents | 7 | 2019 | 2145 | 0.480 |
Why?
| | Preleukemia | 1 | 2015 | 2 | 0.470 |
Why?
| | Infant | 35 | 2025 | 9467 | 0.470 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2016 | 121 | 0.470 |
Why?
| | Drug Hypersensitivity | 3 | 2017 | 89 | 0.450 |
Why?
| | Molecular Targeted Therapy | 3 | 2021 | 414 | 0.450 |
Why?
| | Leukemia, Monocytic, Acute | 1 | 2014 | 4 | 0.450 |
Why?
| | Sarcoma, Myeloid | 1 | 2014 | 4 | 0.440 |
Why?
| | Neoplasm, Residual | 7 | 2023 | 133 | 0.420 |
Why?
| | Adolescent | 41 | 2025 | 21555 | 0.410 |
Why?
| | Bone Marrow Transplantation | 1 | 2014 | 286 | 0.400 |
Why?
| | Medical Oncology | 5 | 2025 | 290 | 0.390 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 26 | 0.390 |
Why?
| | Erwinia | 2 | 2020 | 3 | 0.380 |
Why?
| | Humans | 85 | 2025 | 137514 | 0.370 |
Why?
| | Tumor Suppressor Proteins | 3 | 1999 | 328 | 0.370 |
Why?
| | Acute Kidney Injury | 1 | 2019 | 811 | 0.360 |
Why?
| | Chromosome Aberrations | 2 | 2022 | 157 | 0.360 |
Why?
| | Neutropenia | 2 | 2022 | 146 | 0.350 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2019 | 614 | 0.350 |
Why?
| | Male | 57 | 2025 | 67718 | 0.350 |
Why?
| | Stem Cell Transplantation | 3 | 2019 | 177 | 0.340 |
Why?
| | Rhabdomyosarcoma | 1 | 2011 | 72 | 0.330 |
Why?
| | Cell Cycle Proteins | 3 | 1999 | 614 | 0.330 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 125 | 0.320 |
Why?
| | Carrier Proteins | 3 | 1999 | 770 | 0.320 |
Why?
| | Sarcoma, Ewing | 1 | 2011 | 95 | 0.320 |
Why?
| | Ploidies | 2 | 2019 | 18 | 0.320 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 3 | 2021 | 32 | 0.300 |
Why?
| | Catheter-Related Infections | 2 | 2022 | 80 | 0.300 |
Why?
| | Survival Rate | 8 | 2024 | 1980 | 0.300 |
Why?
| | Genes, Tumor Suppressor | 2 | 1999 | 86 | 0.300 |
Why?
| | Cyclophosphamide | 4 | 2019 | 251 | 0.300 |
Why?
| | Female | 55 | 2025 | 73162 | 0.290 |
Why?
| | Catheterization, Central Venous | 2 | 2022 | 111 | 0.280 |
Why?
| | Philadelphia Chromosome | 2 | 2018 | 18 | 0.280 |
Why?
| | Medication Adherence | 3 | 2017 | 471 | 0.270 |
Why?
| | Gene Deletion | 2 | 1998 | 393 | 0.250 |
Why?
| | Vincristine | 4 | 2021 | 116 | 0.250 |
Why?
| | Trisomy | 2 | 2021 | 83 | 0.250 |
Why?
| | Antimetabolites, Antineoplastic | 2 | 2017 | 94 | 0.250 |
Why?
| | Neoplasm Proteins | 2 | 2018 | 433 | 0.240 |
Why?
| | Etoposide | 2 | 2019 | 157 | 0.240 |
Why?
| | Ikaros Transcription Factor | 1 | 2025 | 24 | 0.230 |
Why?
| | Young Adult | 15 | 2024 | 13243 | 0.230 |
Why?
| | Maryland | 1 | 2024 | 55 | 0.220 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 3 | 1999 | 69 | 0.220 |
Why?
| | Invertebrates | 1 | 2024 | 23 | 0.220 |
Why?
| | Treatment Outcome | 12 | 2023 | 10821 | 0.220 |
Why?
| | Rivers | 1 | 2024 | 64 | 0.220 |
Why?
| | PAX5 Transcription Factor | 2 | 2024 | 14 | 0.210 |
Why?
| | Anxiety | 3 | 2016 | 1041 | 0.210 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2025 | 2193 | 0.200 |
Why?
| | Genomics | 4 | 2025 | 793 | 0.200 |
Why?
| | Gene Rearrangement | 3 | 2019 | 151 | 0.190 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 73 | 0.190 |
Why?
| | Leukemia, Myelomonocytic, Juvenile | 1 | 2022 | 4 | 0.190 |
Why?
| | Induction Chemotherapy | 2 | 2019 | 74 | 0.190 |
Why?
| | Health Equity | 1 | 2024 | 99 | 0.190 |
Why?
| | Polyethylene Glycols | 5 | 2020 | 640 | 0.190 |
Why?
| | Central Venous Catheters | 1 | 2022 | 51 | 0.180 |
Why?
| | Environmental Monitoring | 1 | 2024 | 371 | 0.180 |
Why?
| | Lymphoma | 1 | 2023 | 207 | 0.180 |
Why?
| | Program Evaluation | 2 | 2017 | 892 | 0.180 |
Why?
| | Doxorubicin | 2 | 2022 | 368 | 0.180 |
Why?
| | Prednisone | 2 | 2019 | 245 | 0.180 |
Why?
| | Adult | 23 | 2023 | 37821 | 0.170 |
Why?
| | Lung Neoplasms | 1 | 2014 | 2494 | 0.170 |
Why?
| | Biomarkers, Tumor | 2 | 2025 | 1279 | 0.170 |
Why?
| | Translocation, Genetic | 2 | 2013 | 107 | 0.170 |
Why?
| | Maintenance Chemotherapy | 2 | 2017 | 35 | 0.170 |
Why?
| | Bacterial Infections | 1 | 2022 | 251 | 0.160 |
Why?
| | Immunocompromised Host | 1 | 2021 | 203 | 0.160 |
Why?
| | Diploidy | 1 | 2019 | 18 | 0.160 |
Why?
| | Risk Factors | 11 | 2022 | 10356 | 0.160 |
Why?
| | Genes, p16 | 1 | 1999 | 20 | 0.160 |
Why?
| | Quality of Life | 3 | 2024 | 2870 | 0.150 |
Why?
| | Hyperglycemia | 1 | 2023 | 346 | 0.150 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 1998 | 25 | 0.150 |
Why?
| | Myelodysplastic Syndromes | 1 | 2020 | 135 | 0.150 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 1998 | 55 | 0.150 |
Why?
| | Antibodies, Bispecific | 1 | 2019 | 54 | 0.150 |
Why?
| | Prospective Studies | 9 | 2022 | 7598 | 0.150 |
Why?
| | Rituximab | 1 | 2019 | 178 | 0.150 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 1998 | 73 | 0.150 |
Why?
| | Mutagenesis | 1 | 1999 | 182 | 0.150 |
Why?
| | Prostate-Specific Antigen | 2 | 2009 | 161 | 0.140 |
Why?
| | Patient Safety | 1 | 2021 | 305 | 0.140 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2020 | 179 | 0.140 |
Why?
| | Proto-Oncogenes | 1 | 1997 | 29 | 0.140 |
Why?
| | Family Relations | 2 | 2016 | 89 | 0.140 |
Why?
| | Thioguanine | 1 | 2017 | 19 | 0.140 |
Why?
| | Oncologists | 1 | 2017 | 36 | 0.140 |
Why?
| | Thionucleotides | 1 | 2017 | 36 | 0.140 |
Why?
| | Apyrase | 1 | 2017 | 17 | 0.140 |
Why?
| | Follow-Up Studies | 6 | 2021 | 5139 | 0.130 |
Why?
| | Blast Crisis | 1 | 2016 | 33 | 0.130 |
Why?
| | Carboxypeptidases A | 1 | 2016 | 2 | 0.130 |
Why?
| | Pediatricians | 1 | 2017 | 131 | 0.130 |
Why?
| | Retrospective Studies | 10 | 2023 | 15628 | 0.120 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 285 | 0.120 |
Why?
| | Sepsis | 1 | 2022 | 611 | 0.120 |
Why?
| | Osteonecrosis | 1 | 2015 | 23 | 0.120 |
Why?
| | Depression | 2 | 2016 | 1408 | 0.120 |
Why?
| | Nausea | 1 | 2016 | 115 | 0.120 |
Why?
| | Mentors | 2 | 2017 | 197 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 1 | 2019 | 555 | 0.120 |
Why?
| | Pancreatitis | 1 | 2016 | 132 | 0.120 |
Why?
| | Central Nervous System Neoplasms | 1 | 2017 | 158 | 0.120 |
Why?
| | Monitoring, Physiologic | 1 | 2017 | 267 | 0.120 |
Why?
| | Longitudinal Studies | 7 | 2016 | 2857 | 0.120 |
Why?
| | Mentoring | 1 | 2017 | 144 | 0.110 |
Why?
| | Dexamethasone | 4 | 2021 | 377 | 0.110 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2016 | 69 | 0.110 |
Why?
| | Mutation | 4 | 2022 | 3964 | 0.110 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 3 | 1999 | 16 | 0.110 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 2 | 2010 | 70 | 0.110 |
Why?
| | Cross Infection | 1 | 2016 | 238 | 0.110 |
Why?
| | Bacteremia | 1 | 2016 | 209 | 0.110 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 538 | 0.110 |
Why?
| | Antigens, CD | 1 | 2017 | 524 | 0.110 |
Why?
| | Flow Cytometry | 1 | 2018 | 1185 | 0.110 |
Why?
| | Repressor Proteins | 1 | 1997 | 425 | 0.110 |
Why?
| | Life Change Events | 1 | 2014 | 153 | 0.100 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2013 | 44 | 0.100 |
Why?
| | Pediatrics | 3 | 2021 | 1123 | 0.100 |
Why?
| | Histone-Lysine N-Methyltransferase | 2 | 2010 | 141 | 0.100 |
Why?
| | Immunotherapy | 1 | 2018 | 647 | 0.100 |
Why?
| | DNA-Binding Proteins | 2 | 1998 | 1507 | 0.100 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 313 | 0.100 |
Why?
| | Quality Improvement | 1 | 2021 | 1161 | 0.100 |
Why?
| | Leukemia, Megakaryoblastic, Acute | 1 | 2012 | 10 | 0.100 |
Why?
| | Transcription Factors | 2 | 1998 | 1717 | 0.100 |
Why?
| | Karyotyping | 3 | 2019 | 107 | 0.100 |
Why?
| | Myeloproliferative Disorders | 1 | 2012 | 29 | 0.100 |
Why?
| | Self Report | 1 | 2017 | 831 | 0.100 |
Why?
| | Contraindications | 1 | 2012 | 90 | 0.090 |
Why?
| | Arabinonucleosides | 1 | 2011 | 8 | 0.090 |
Why?
| | Adenine Nucleotides | 1 | 2011 | 23 | 0.090 |
Why?
| | Cohort Studies | 5 | 2021 | 5730 | 0.090 |
Why?
| | Prostatic Neoplasms | 2 | 2009 | 1034 | 0.090 |
Why?
| | Antibodies, Monoclonal | 1 | 2018 | 1428 | 0.090 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2010 | 19 | 0.080 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2010 | 30 | 0.080 |
Why?
| | Multivariate Analysis | 4 | 2015 | 1524 | 0.080 |
Why?
| | Pain | 1 | 2016 | 836 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1999 | 0.080 |
Why?
| | Parents | 2 | 2016 | 1363 | 0.080 |
Why?
| | Age Factors | 8 | 2019 | 3301 | 0.080 |
Why?
| | Prostatectomy | 1 | 2009 | 104 | 0.080 |
Why?
| | Bloom Syndrome | 1 | 1988 | 3 | 0.070 |
Why?
| | Neoplasm Metastasis | 1 | 2011 | 659 | 0.070 |
Why?
| | Gene Expression Regulation, Leukemic | 2 | 2016 | 53 | 0.070 |
Why?
| | Juxtaglomerular Apparatus | 1 | 2007 | 1 | 0.070 |
Why?
| | Risk Assessment | 4 | 2024 | 3439 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 1061 | 0.070 |
Why?
| | Blood Coagulation | 1 | 2008 | 254 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 784 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2024 | 1047 | 0.060 |
Why?
| | Stress, Psychological | 1 | 2014 | 1115 | 0.060 |
Why?
| | Surveys and Questionnaires | 4 | 2024 | 5772 | 0.060 |
Why?
| | Animals | 3 | 2024 | 37011 | 0.060 |
Why?
| | Methotrexate | 2 | 2017 | 260 | 0.060 |
Why?
| | Remission Induction | 2 | 2019 | 287 | 0.060 |
Why?
| | Drug Monitoring | 2 | 2017 | 221 | 0.060 |
Why?
| | Acute Disease | 2 | 2019 | 1008 | 0.060 |
Why?
| | Case-Control Studies | 3 | 2024 | 3546 | 0.060 |
Why?
| | Selection Bias | 1 | 2024 | 37 | 0.050 |
Why?
| | Personal Satisfaction | 2 | 2017 | 211 | 0.050 |
Why?
| | Administration, Oral | 2 | 2017 | 814 | 0.050 |
Why?
| | Incidence | 3 | 2019 | 2792 | 0.050 |
Why?
| | Genetic Variation | 1 | 1988 | 986 | 0.050 |
Why?
| | Kidney Neoplasms | 1 | 2007 | 400 | 0.050 |
Why?
| | Risk | 5 | 2023 | 905 | 0.050 |
Why?
| | Disease Progression | 2 | 2021 | 2755 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2020 | 1465 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-cbl | 1 | 2022 | 12 | 0.050 |
Why?
| | Transcriptome | 2 | 2019 | 974 | 0.050 |
Why?
| | Exome | 1 | 2022 | 231 | 0.040 |
Why?
| | Drug Therapy | 1 | 2021 | 84 | 0.040 |
Why?
| | Menorrhagia | 1 | 2001 | 22 | 0.040 |
Why?
| | Diarrhea | 2 | 1999 | 183 | 0.040 |
Why?
| | Bone Marrow | 1 | 2022 | 286 | 0.040 |
Why?
| | Endocrine Glands | 1 | 1979 | 15 | 0.040 |
Why?
| | Blood Cell Count | 1 | 1999 | 54 | 0.040 |
Why?
| | Chromosomes, Human | 1 | 2019 | 44 | 0.040 |
Why?
| | Viral Load | 1 | 2021 | 462 | 0.040 |
Why?
| | Azacitidine | 1 | 2020 | 141 | 0.040 |
Why?
| | Cytogenetic Analysis | 1 | 2019 | 34 | 0.040 |
Why?
| | Loss of Heterozygosity | 1 | 1999 | 51 | 0.040 |
Why?
| | Genome-Wide Association Study | 2 | 2016 | 1436 | 0.040 |
Why?
| | Mosaicism | 1 | 2019 | 73 | 0.040 |
Why?
| | Disinfectants | 1 | 1999 | 38 | 0.040 |
Why?
| | Sequence Deletion | 1 | 1999 | 183 | 0.040 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2018 | 47 | 0.040 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2020 | 228 | 0.040 |
Why?
| | Chromosomes | 1 | 2019 | 108 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2021 | 767 | 0.040 |
Why?
| | Infant, Newborn | 4 | 2019 | 6059 | 0.040 |
Why?
| | Escherichia coli O157 | 1 | 1998 | 31 | 0.040 |
Why?
| | Hypertension | 1 | 2007 | 1293 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 554 | 0.040 |
Why?
| | United States | 4 | 2021 | 14696 | 0.040 |
Why?
| | Methylation | 1 | 1998 | 237 | 0.040 |
Why?
| | Community Participation | 1 | 1999 | 131 | 0.030 |
Why?
| | Erythrocyte Count | 1 | 2017 | 20 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 2 | 2017 | 2420 | 0.030 |
Why?
| | Biopsy | 1 | 2021 | 1132 | 0.030 |
Why?
| | Glucose | 1 | 2023 | 1018 | 0.030 |
Why?
| | Escherichia coli Infections | 1 | 1998 | 111 | 0.030 |
Why?
| | Food-Drug Interactions | 1 | 2017 | 9 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2017 | 80 | 0.030 |
Why?
| | Injections, Intramuscular | 1 | 2017 | 128 | 0.030 |
Why?
| | Career Mobility | 1 | 2017 | 67 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 1997 | 56 | 0.030 |
Why?
| | Leucovorin | 1 | 2017 | 83 | 0.030 |
Why?
| | Family | 1 | 2021 | 667 | 0.030 |
Why?
| | Cranial Irradiation | 1 | 2017 | 69 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2021 | 950 | 0.030 |
Why?
| | Dairy Products | 1 | 2017 | 36 | 0.030 |
Why?
| | Water Purification | 1 | 1999 | 153 | 0.030 |
Why?
| | Cerebrospinal Fluid | 1 | 2017 | 94 | 0.030 |
Why?
| | MEF2 Transcription Factors | 1 | 2016 | 61 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2017 | 411 | 0.030 |
Why?
| | Luciferases | 1 | 2016 | 151 | 0.030 |
Why?
| | Sulfonamides | 1 | 2020 | 513 | 0.030 |
Why?
| | NIH 3T3 Cells | 1 | 2016 | 144 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2017 | 331 | 0.030 |
Why?
| | Hemorrhage | 1 | 2001 | 723 | 0.030 |
Why?
| | Methyltransferases | 1 | 2017 | 78 | 0.030 |
Why?
| | Methyl Ethers | 1 | 1996 | 13 | 0.030 |
Why?
| | Ethers | 1 | 1996 | 19 | 0.030 |
Why?
| | Bone Morphogenetic Protein 7 | 1 | 2015 | 10 | 0.030 |
Why?
| | Fluorides | 1 | 1996 | 50 | 0.030 |
Why?
| | Cytarabine | 1 | 2016 | 61 | 0.030 |
Why?
| | Anesthetics, Inhalation | 1 | 1996 | 35 | 0.030 |
Why?
| | Health Education | 1 | 1999 | 343 | 0.030 |
Why?
| | Breast Neoplasms | 5 | 1979 | 2249 | 0.030 |
Why?
| | Genotype | 3 | 2017 | 1920 | 0.030 |
Why?
| | Middle Aged | 10 | 2019 | 33355 | 0.030 |
Why?
| | Spinal Dysraphism | 1 | 1996 | 79 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2017 | 2838 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2017 | 227 | 0.030 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2016 | 211 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 625 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 1998 | 504 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2016 | 233 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 734 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 1999 | 1255 | 0.030 |
Why?
| | Qualitative Research | 1 | 2021 | 1361 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2016 | 451 | 0.030 |
Why?
| | DNA Methylation | 1 | 1999 | 644 | 0.030 |
Why?
| | Algorithms | 1 | 2021 | 1702 | 0.030 |
Why?
| | Psychomotor Agitation | 1 | 2014 | 70 | 0.030 |
Why?
| | Behavior | 1 | 2014 | 95 | 0.030 |
Why?
| | Aged | 9 | 2019 | 23798 | 0.030 |
Why?
| | Income | 1 | 2014 | 201 | 0.030 |
Why?
| | Demography | 1 | 2014 | 292 | 0.030 |
Why?
| | Marriage | 1 | 2014 | 121 | 0.030 |
Why?
| | Base Sequence | 1 | 2016 | 2180 | 0.030 |
Why?
| | Blood Glucose | 1 | 2023 | 2183 | 0.020 |
Why?
| | Prevalence | 2 | 2016 | 2719 | 0.020 |
Why?
| | Odds Ratio | 1 | 2015 | 1063 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2013 | 319 | 0.020 |
Why?
| | Nucleoside Transport Proteins | 1 | 2011 | 7 | 0.020 |
Why?
| | Aggression | 1 | 2014 | 210 | 0.020 |
Why?
| | Kidney | 2 | 1996 | 1472 | 0.020 |
Why?
| | Time Factors | 2 | 2015 | 6817 | 0.020 |
Why?
| | Regression Analysis | 1 | 2014 | 1029 | 0.020 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2011 | 73 | 0.020 |
Why?
| | Erythrocytes | 1 | 2017 | 693 | 0.020 |
Why?
| | Escherichia coli | 1 | 2015 | 815 | 0.020 |
Why?
| | Mice | 2 | 2019 | 17843 | 0.020 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2011 | 190 | 0.020 |
Why?
| | Survival Analysis | 1 | 2013 | 1320 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 2064 | 0.020 |
Why?
| | Bacteria | 1 | 2016 | 858 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 2974 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 892 | 0.020 |
Why?
| | Sister Chromatid Exchange | 1 | 1988 | 4 | 0.020 |
Why?
| | Genetic Complementation Test | 1 | 1988 | 66 | 0.020 |
Why?
| | Cell Fusion | 1 | 1988 | 51 | 0.020 |
Why?
| | Emotions | 1 | 2014 | 590 | 0.020 |
Why?
| | Water Microbiology | 2 | 1999 | 85 | 0.020 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2008 | 86 | 0.020 |
Why?
| | Protein C | 1 | 2008 | 59 | 0.020 |
Why?
| | Antithrombins | 1 | 2008 | 59 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 5792 | 0.020 |
Why?
| | Fibrinogen | 1 | 2008 | 170 | 0.020 |
Why?
| | Genetic Markers | 1 | 1988 | 345 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2008 | 416 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2007 | 191 | 0.020 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 84 | 0.020 |
Why?
| | Rare Diseases | 1 | 2007 | 101 | 0.020 |
Why?
| | Blood Pressure Determination | 1 | 2007 | 156 | 0.020 |
Why?
| | Nephrectomy | 1 | 2007 | 168 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4172 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2011 | 2838 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2007 | 1740 | 0.010 |
Why?
| | Cell Line | 1 | 1988 | 2852 | 0.010 |
Why?
| | Anemia, Hypochromic | 1 | 2001 | 3 | 0.010 |
Why?
| | Blood Platelet Disorders | 1 | 2001 | 10 | 0.010 |
Why?
| | von Willebrand Diseases | 1 | 2001 | 27 | 0.010 |
Why?
| | Estriol | 1 | 1979 | 8 | 0.010 |
Why?
| | Estrone | 1 | 1979 | 37 | 0.010 |
Why?
| | Menstruation | 1 | 1979 | 43 | 0.010 |
Why?
| | Prolactin | 1 | 1979 | 100 | 0.010 |
Why?
| | Thrombocytopenia | 1 | 2001 | 199 | 0.010 |
Why?
| | Bolivia | 1 | 1999 | 65 | 0.010 |
Why?
| | Luteinizing Hormone | 1 | 1979 | 185 | 0.010 |
Why?
| | Follicle Stimulating Hormone | 1 | 1979 | 244 | 0.010 |
Why?
| | Restaurants | 1 | 1998 | 25 | 0.010 |
Why?
| | Swimming | 1 | 1998 | 50 | 0.010 |
Why?
| | Food Handling | 1 | 1998 | 60 | 0.010 |
Why?
| | Progesterone | 1 | 1979 | 251 | 0.010 |
Why?
| | Disease Transmission, Infectious | 1 | 1998 | 61 | 0.010 |
Why?
| | Water Supply | 1 | 1998 | 78 | 0.010 |
Why?
| | Meat | 1 | 1998 | 94 | 0.010 |
Why?
| | Kyphosis | 1 | 1996 | 39 | 0.010 |
Why?
| | Halothane | 1 | 1996 | 7 | 0.010 |
Why?
| | Estradiol | 1 | 1979 | 513 | 0.010 |
Why?
| | Congenital Abnormalities | 1 | 1996 | 88 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1999 | 1324 | 0.010 |
Why?
| | Population Surveillance | 1 | 1999 | 474 | 0.010 |
Why?
| | Feces | 1 | 1998 | 479 | 0.010 |
Why?
| | Diagnostic Imaging | 1 | 1996 | 339 | 0.010 |
Why?
| | Ovarian Neoplasms | 1 | 1978 | 563 | 0.010 |
Why?
| | Pedigree | 3 | 1978 | 514 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 1999 | 7593 | 0.000 |
Why?
| | Nebraska | 2 | 1976 | 18 | 0.000 |
Why?
| | New York | 2 | 1976 | 133 | 0.000 |
Why?
| | Genes | 1 | 1978 | 230 | 0.000 |
Why?
| | Genetic Linkage | 1 | 1978 | 299 | 0.000 |
Why?
| | Oncogenic Viruses | 1 | 1976 | 3 | 0.000 |
Why?
| | Apocrine Glands | 1 | 1976 | 4 | 0.000 |
Why?
| | Genetic Techniques | 1 | 1976 | 64 | 0.000 |
Why?
| | Pheochromocytoma | 1 | 1976 | 58 | 0.000 |
Why?
| | Klinefelter Syndrome | 1 | 1976 | 62 | 0.000 |
Why?
| | Syndrome | 1 | 1976 | 359 | 0.000 |
Why?
| | Statistics as Topic | 1 | 1976 | 316 | 0.000 |
Why?
| | HLA Antigens | 1 | 1976 | 237 | 0.000 |
Why?
| | Abnormalities, Multiple | 1 | 1976 | 189 | 0.000 |
Why?
| | Pregnancy | 2 | 1978 | 6745 | 0.000 |
Why?
| | Skin Diseases | 1 | 1976 | 149 | 0.000 |
Why?
| | Sarcoma | 1 | 1976 | 192 | 0.000 |
Why?
| | Sex Factors | 1 | 1978 | 2074 | 0.000 |
Why?
| | Thyroid Neoplasms | 1 | 1976 | 338 | 0.000 |
Why?
| | Neoplasms | 2 | 1976 | 2666 | 0.000 |
Why?
| | Melanoma | 1 | 1976 | 758 | 0.000 |
Why?
| | Registries | 1 | 1976 | 2021 | 0.000 |
Why?
| | Phenotype | 1 | 1976 | 3205 | 0.000 |
Why?
| | Brain Neoplasms | 1 | 1976 | 1241 | 0.000 |
Why?
|
|
Maloney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|